Ultragenyx Pharmaceutical Inc.’s Debt to Equity at a glance
Ultragenyx Pharmaceutical Inc. reports debt to equity of 3.56 for Dec 2024. The prior period recorded 0.16 (Dec 2023). Year over year the metric moved +3.41 (+2,174.1%). The rolling three-period average stands at 1.27. Data last refreshed Dec 7, 2025, 2:53 AM.
Latest reading
3.56 · Dec 2024
YoY movement
+3.41 (+2,174.1%)
Rolling average
1.27
Current Debt to Equity
3.56
+3.41
+2,174.1%
Rolling average
1.27
Latest Value
3.56
Dec 2024
YoY Change
+3.41
Absolute
YoY Change %
+2,174.1%
Rate of change
3-Period Avg
1.27
Smoothed
Narrative signal
Ultragenyx Pharmaceutical Inc.’s debt to equity stands at 3.56 for Dec 2024. Year-over-year, the metric shifted by +3.41, translating into a +2,174.1% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How debt to equity shapes Ultragenyx Pharmaceutical Inc.'s story
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports debt to equity of 3.56. Study leverage posture, capital structure discipline, and balance sheet risk across multi-year periods.
Interpreting leverage levels
A rising debt-to-equity ratio shows greater reliance on borrowing. Moderate leverage can enhance returns, but excessive leverage increases financial risk in downturns.
Benchmarking within an industry
Capital intensity differs by industry. Utilities and telecom often run higher leverage while software firms trend lower. Always compare against relevant peers.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
86.3%
Operating Margin
-95.7%
Net Profit Margin
-101.6%
Return on Equity
-222.9%
Return on Assets
-37.9%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Ultragenyx Pharmaceutical Inc. (RARE) FAQs
Answers tailored to Ultragenyx Pharmaceutical Inc.’s debt to equity profile using the latest Financial Modeling Prep data.
What is Ultragenyx Pharmaceutical Inc.'s current debt to equity?
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports debt to equity of 3.56. This reading reflects the latest filings and price data for RARE.
How is Ultragenyx Pharmaceutical Inc.'s debt to equity trending year over year?
Year-over-year, the figure shifts by +3.41 (+2,174.1%). Pair this context with revenue growth and free cash flow signals to gauge momentum for RARE.
Why does debt to equity matter for Ultragenyx Pharmaceutical Inc.?
The debt-to-equity ratio compares total liabilities with shareholders’ equity to illustrate leverage. For Ultragenyx Pharmaceutical Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Ultragenyx Pharmaceutical Inc.'s debt to equity above its recent average?
Ultragenyx Pharmaceutical Inc.'s rolling three-period average sits at 1.27. Comparing the latest reading of 3.56 to that baseline highlights whether momentum is building or fading for RARE.
How frequently is Ultragenyx Pharmaceutical Inc.'s debt to equity refreshed?
Data for RARE was last refreshed on Dec 7, 2025, 2:53 AM and updates automatically every 24 hours, keeping your valuation inputs current.